Success Metrics

Clinical Success Rate
62.5%

Based on 5 completed trials

Completion Rate
63%(5/8)
Active Trials
2(15%)
Results Posted
80%(4 trials)
Terminated
3(23%)

Phase Distribution

Ph phase_4
6
46%
Ph phase_3
2
15%
Ph phase_2
4
31%
Ph phase_1
1
8%

Phase Distribution

1

Early Stage

4

Mid Stage

8

Late Stage

Phase Distribution13 total trials
Phase 1Safety & dosage
1(7.7%)
Phase 2Efficacy & side effects
4(30.8%)
Phase 3Large-scale testing
2(15.4%)
Phase 4Post-market surveillance
6(46.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

62.5%

5 of 8 finished

Non-Completion Rate

37.5%

3 ended early

Currently Active

2

trials recruiting

Total Trials

13

all time

Status Distribution
Active(3)
Completed(5)
Terminated(3)
Other(2)

Detailed Status

Completed5
Terminated3
unknown2
Active, not recruiting1
Recruiting1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
2
Success Rate
62.5%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (7.7%)
Phase 24 (30.8%)
Phase 32 (15.4%)
Phase 46 (46.2%)

Trials by Status

completed538%
unknown215%
active_not_recruiting18%
recruiting18%
not_yet_recruiting18%
terminated323%

Recent Activity

2 active trials
Showing 5 of 13
recruitingphase_2

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

NCT07138898
not_yet_recruitingphase_4

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

NCT07352566
active_not_recruitingphase_2

BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)

NCT05156710
terminatedphase_4

Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol

NCT00866684
terminatedphase_2

Baricitinib for the Treatment of Ocular Mucous Membrane Pemphigoid

NCT05263505
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT07138898Phase 2

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

Recruiting
NCT07352566Phase 4

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

Not Yet Recruiting
NCT05156710Phase 2

BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)

Active Not Recruiting
NCT00866684Phase 4

Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol

Terminated
NCT05263505Phase 2

Baricitinib for the Treatment of Ocular Mucous Membrane Pemphigoid

Terminated
NCT04424602Phase 4

Comparison between2 Drugs in Lupus Nephritis

Completed
NCT04945096Phase 3

Outcomes of Patients After Allo-HSCT With Decitabine and NAC

Unknown
NCT02152345Phase 4

Belatacept Compared to Tacrolimus in Deceased Donor Renal Transplant Recipients

Completed
NCT01490723Phase 2

Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)

Completed
NCT02167958Phase 1

Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source

Completed
NCT00262132Phase 3

Mycophenolate for Pulmonary Sarcoidosis

Terminated
NCT02453867Phase 4

Efficacy and Safety of a Reduced Immunosuppression vs. Standard Triple Therapy in Senior Renal Transplant Recipients

Unknown
NCT02683291Phase 4

Sirolimus Associated With Tacrolimus at Low Doses in Elderly Kidney Transplant Patients

Completed

All 13 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
13